Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Syros Pharmaceuticals, Inc. (SYRS : NSDQ)
 
 • Company Description   
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Number of Employees: 118

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.70 Daily Weekly Monthly
20 Day Moving Average: 87,956 shares
Shares Outstanding: 20.60 (millions)
Market Capitalization: $76.20 (millions)
Beta: 1.67
52 Week High: $11.50
52 Week Low: $2.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 18.59% 14.10%
12 Week 2.49% -4.86%
Year To Date 3.06% -6.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
35 Cambridge Park Drive 4th Floor
-
CAMBRIDGE,MA 02140
USA
ph: 617-744-1340
fax: -
khunady@syros.com http://www.syros.com
 
 • General Corporate Information   
Officers
Nancy Simonian - President; Chief Executive Officer and Director
Peter Wirth - Chairman
Jason Haas - Chief Financial Officer
Srinivas Akkaraju - Director
Mark J. Alles - Director

Peer Information
Syros Pharmaceuticals, Inc. (CORR.)
Syros Pharmaceuticals, Inc. (RSPI)
Syros Pharmaceuticals, Inc. (CGXP)
Syros Pharmaceuticals, Inc. (BGEN)
Syros Pharmaceuticals, Inc. (GTBP)
Syros Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87184Q206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/08/23
Share - Related Items
Shares Outstanding: 20.60
Most Recent Split Date: 9.00 (0.10:1)
Beta: 1.67
Market Capitalization: $76.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.71
Price/Cash Flow: -
Price / Sales: 3.25
EPS Growth
vs. Year Ago Period: 78.75%
vs. Previous Quarter: 33.59%
Sales Growth
vs. Year Ago Period: -45.97%
vs. Previous Quarter: -%
ROE
03/31/23 - -118.11
12/31/22 - -134.48
09/30/22 - -141.16
ROA
03/31/23 - -54.16
12/31/22 - -58.40
09/30/22 - -58.31
Current Ratio
03/31/23 - 7.37
12/31/22 - 6.87
09/30/22 - 6.57
Quick Ratio
03/31/23 - 7.37
12/31/22 - 6.87
09/30/22 - 6.57
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -464.01
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -485.12
Pre-Tax Margin
03/31/23 - -754.40
12/31/22 - -636.12
09/30/22 - -485.12
Book Value
03/31/23 - 5.18
12/31/22 - 6.32
09/30/22 - 6.39
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.37
12/31/22 - 0.32
09/30/22 - 0.31
Debt-to-Capital
03/31/23 - 26.82
12/31/22 - 24.14
09/30/22 - 23.88
 

Powered by Zacks Investment Research ©